全文获取类型
收费全文 | 2768篇 |
免费 | 182篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 76篇 |
妇产科学 | 47篇 |
基础医学 | 426篇 |
口腔科学 | 58篇 |
临床医学 | 190篇 |
内科学 | 653篇 |
皮肤病学 | 50篇 |
神经病学 | 135篇 |
特种医学 | 169篇 |
外科学 | 310篇 |
综合类 | 74篇 |
一般理论 | 1篇 |
预防医学 | 89篇 |
眼科学 | 14篇 |
药学 | 126篇 |
中国医学 | 1篇 |
肿瘤学 | 524篇 |
出版年
2023年 | 13篇 |
2022年 | 23篇 |
2021年 | 50篇 |
2020年 | 38篇 |
2019年 | 57篇 |
2018年 | 63篇 |
2017年 | 41篇 |
2016年 | 47篇 |
2015年 | 63篇 |
2014年 | 65篇 |
2013年 | 90篇 |
2012年 | 130篇 |
2011年 | 110篇 |
2010年 | 76篇 |
2009年 | 96篇 |
2008年 | 122篇 |
2007年 | 112篇 |
2006年 | 135篇 |
2005年 | 97篇 |
2004年 | 93篇 |
2003年 | 93篇 |
2002年 | 96篇 |
2001年 | 81篇 |
2000年 | 95篇 |
1999年 | 112篇 |
1998年 | 80篇 |
1997年 | 65篇 |
1996年 | 61篇 |
1995年 | 35篇 |
1994年 | 30篇 |
1993年 | 38篇 |
1992年 | 57篇 |
1991年 | 53篇 |
1990年 | 51篇 |
1989年 | 55篇 |
1988年 | 62篇 |
1987年 | 49篇 |
1986年 | 49篇 |
1985年 | 43篇 |
1984年 | 15篇 |
1983年 | 20篇 |
1982年 | 13篇 |
1979年 | 15篇 |
1978年 | 17篇 |
1977年 | 12篇 |
1976年 | 11篇 |
1973年 | 13篇 |
1969年 | 11篇 |
1967年 | 10篇 |
1966年 | 15篇 |
排序方式: 共有2961条查询结果,搜索用时 234 毫秒
991.
Rosa Sottile Pradeepa N. Pangigadde Thomas Tan Andrea Anichini Francesco Sabbatino Francesca Trecroci Elvira Favoino Laura Orgiano James Roberts Soldano Ferrone Klas Kärre Ennio Carbone 《European journal of immunology》2016,46(2):409-419
The frequent development of drug resistance to targeted therapies in cancer patients has stimulated interest in strategies counteracting resistance. Combining immunotherapies with targeted therapies is one such strategy. In this context, we asked whether human NK cells can target melanoma cells that have acquired resistance to selective inhibitors targeting activating mutants of the B‐Raf kinase (BRAF inhibitors, BRAFi). We generated drug‐resistant cell variants in vitro from human BRAF‐mutant melanoma cell lines MEL‐HO, COLO‐38, SK‐MEL‐37, 1520 and from primary melanoma cells freshly isolated from two patients. All drug‐resistant cell variants remained susceptible to lysis by IL‐2‐activated NK cells; and two BRAFi‐resistant lines (BRAFi‐R) became significantly more susceptible to NK‐cell lysis than their parental lines. This was associated with significant HLA class I antigen downregulation and PD‐L1 upregulation on the drug‐resistant lines. Although blocking HLA class I enhanced the extent of lysis of both BRAFi‐R and parental cells to NK‐cell‐mediated lysis, antibody‐mediated inhibition of PD1–PD‐L1 interactions had no detectable effect. HLA class I antigen expression on BRAFi‐R melanoma variants thus appears to play a major role in their susceptibility to NK‐cell cytotoxicity. These findings suggest that NK‐cell‐based immunotherapy may be a viable approach to treat melanoma patients with acquired resistance to BRAF inhibitors. 相似文献
992.
993.
994.
995.
996.
Ming-Sound Tsao Michele Carbone Francoise Galateau-Salle Andre L. Moreira Andrew G. Nicholson Anja C. Roden Alex A. Adjei Marie-Christine Aubry Dean A. Fennell Daniel Gomez David Harpole Mary Hesdorffer Fred R. Hirsch Geoffrey Liu Shakun Malik Anna Nowak Tobias Peikert Ravi Salgia Aaron S. Mansfield 《Journal of thoracic oncology》2019,14(10):1704-1717
The accurate diagnosis of mesothelioma is critical for the appropriate clinical management of this cancer. Many issues complicate making the diagnosis of mesothelioma including the presence of reactive mesothelial cells in benign pleural effusions, the heterogeneity of mesothelioma histopathology, the relatively high incidence of other epithelial malignancies that metastasize to the pleura, and primary sarcomas that arise within the pleura. Given the rapidly evolving field of molecular profiling and the need for translational correlates in mesothelioma clinical trials, the National Cancer Institute (NCI)–International Association for the Study of Lung Cancer–Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting was convened in March 2017 to develop a consensus on standard pathology guidelines for future NCI-sponsored clinical trials in mesothelioma. This consensus statement covers recommendations for specimen handling, pathologic classification and diagnosis, biobanking, and tissue correlative studies. 相似文献
997.
Ximena Calderón‐Castrat M.D. Alex Orellana Cortez M.D. Beatriz Ingar Carbone M.D. Angel Santos‐Briz M.D. 《Pediatric dermatology》2017,34(4):e216-e218
Fibroblastic connective tissue nevus (FCTN) is a rare, benign, dermal mesenchymal hamartoma that affects children. We report a 15‐year‐old boy with a congenital FCTN and describe the clinical, dermatoscopic, and histopathologic features. 相似文献
998.
999.
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression 总被引:10,自引:2,他引:10
Ohm JE Gabrilovich DI Sempowski GD Kisseleva E Parman KS Nadaf S Carbone DP 《Blood》2003,101(12):4878-4886
T-cell defects and premature thymic atrophy occur in cancer patients and tumor-bearing animals. We demonstrate that exposure of mice to recombinant vascular endothelial growth factor (VEGF) at concentrations similar to those observed in advanced stage cancer patients reproduces this profound thymic atrophy and is highlighted by a dramatic reduction in CD4+/CD8+ thymocytes. We find that VEGF does not induce thymocyte apoptosis, but instead rapidly decreases the number of the earliest observable progenitors in the thymus. VEGF does not inhibit thymocyte development in fetal thymic organ culture, further suggesting a prethymic effect. We also demonstrate that bone marrow progenitors from animals infused with recombinant VEGF and transferred to irradiated untreated animals recolonize the thymus more efficiently than progenitors from control animals. This suggests that VEGF exposure is associated with an increased population of thymus-committed progenitors in the bone marrow. We hypothesize that pathophysiologically relevant concentrations of VEGF may block the differentiation and/or emigration of these progenitors resulting in the observed thymic atrophy. Removal of VEGF via cessation of infusion or adoptive transfer of progenitors to a congenic host induces a preferential commitment of lymphoid progenitors to the T lineage and results in a restoration of the normal composition and cellularity of the thymus. These data demonstrate that at pathophysiologic concentrations, VEGF interferes with the development of T cells from early hematopoetic progenitor cells and this may contribute to tumor-associated immune deficiencies. 相似文献
1000.
V. Zagonel U. Tirelli A. Veronesi E. Galligioni S. Tumolo M. Roncadin A. Carbone E. Grigoletto 《Annals of hematology》1986,52(1):59-61
Summary Teniposide has been evaluated in a phase II clinical trial in chronic lymphocytic leukemia (CLL). Among 16 consecutive patients with CLL entered in the study and treated with Teniposide, 100 mg/m2 weekly, no objective response was observed. Toxicity was generally mild and mainly hematologic. Teniposide at this dosage and schedule is an inactive drug in CLL. 相似文献